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Abstract
Aldosterone synthase deficiency (ASD) is a rare autosomal recessive disorder characterized by severe hyperkalemia, salt loss, vomiting, severe dehydration and failure to thrive. ASD is a life-threatening electrolyte imbalance in infants resulting from mutations in CYP11B2. We described ASD in a Chinese male infant with vomiting, poor feeding and failure to thrive. He was mildly dehydrated, with a weight of 6 kg (-3.45 SDS) and length of 67 cm (-3.10 SDS). Laboratory tests showed hyponatremia (119 mmol/L), serum potassium 5.4 mmol/L, low plasma aldosterone and plasma renin activity (PRA) levels. Next-generation sequencing of his DNA revealed compound heterozygous mutations in CYP11B2, a known variant c.1391_1393delTGC
(p.Leu464del, rs776404064) and a novel variant c.1294delA (p.Arg432Glyfs*37). The HEK-293T expression system was used to investigate the variants, demonstrating negligible aldosterone synthesis compared with WT CYP11B2. The patient started fludrocortisone and subsequently gained 3.2 kg of weight and normalized serum sodium (137 mmol/L). We further reviewed reported cases of ASD, summarizing clinical features and CYP11B2 mutations; missense and nonsense mutations are most frequent. Fludrocortisone treatment is essential for ASD, and the need for mineralocorticoid replacement wanes with age; eventually, therapy can be discontinued for many affected children. Our study broadens the ASD phenotypic spectrum and shows the efficiency of next-generation sequencing for patients with atypical clinical manifestations.
Abbreviations: ASD, aldosterone synthase deficiency; CMO, corticosterone methyl oxidase; DOC, 11-deoxycorticosterone; PRA, plasma renin activity; NGS, nextgeneration sequencing; HPLC, high-performance liquid chromatography.
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Introduction
Aldosterone is produced in the zona glomerulosa of adrenal cortex and is the most important mineralocorticoid hormone in humans. Aldosterone is mainly responsible for electrolyte balance. Aldosterone not only regulates sodium absorption and intravascular volume but also potassium excretion via distal convoluted tubules and renal cortex collecting ducts [1] . Aldosterone synthase deficiency (ASD) is a rare autosomal recessive disorder that causes life-threatening electrolyte imbalance in infants. Affected children often display hyperkalemia, salt loss, vomiting, severe dehydration and failure to thrive in the first months of life [2, 3] . This disease is mainly due to loss-of-functional mutations in the gene CYP11B2, which is located on chromosome 8q24.3 and contains 9 exons and 503 amino acids [4] . CYP11B2 encodes the cytochrome P450 enzyme aldosterone synthase [1] . This enzyme catalyzes the final three steps in aldosterone biosynthesis as follows: the 11β-hydroxylation of 11-deoxycorticosterone (DOC) to form corticosterone, the 18-hydroxylation of corticosterone to form 18-hydroxycorticosterone, and finally, the 18-oxidation of 18-hydroxycorticosterone to form aldosterone [5, 6] .
There are two types of ASD, formerly known as corticosterone methyl oxidase deficiency type 1 (CMO I) and type 2 (CMO II) based on the specific defects in aldosterone synthesis. These two types of ASD both present low aldosterone levels and elevated plasma renin activity but can be distinguished by the production of 18-hydroxycorticosterone. ASD Type 1 or CMO I affects the hydroxylation of corticosterone and thus exhibits decreased levels of 18-hydroxycorticosterone, while ASD type 2 or CMO II patients show markedly elevated levels of 18-hydroxycorticosterone due to defects restricted to the oxidation of 18-hydroxycorticosterone to aldosterone [6, 7] .
Reduced mineralocorticoids can be found in other diseases, the most common cause of which is congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD).
Patients with salt-wasting 21OHD may show signs of severe renal salt loss, which can be life-threatening during the first weeks of life. Unlike ASD, 21OHD also features cortisol deficiency, genital virilization in affected females, and elevated serum 17-hydroxyprogesterone (17OHP). These patients often carry inactivating mutations in the 21-hydroxylase gene (CYP21A2) . But Elevated 17OHP could also be found in newborns not only with pathological condition such as preterm birth, infection and stress but also with other types of congenital adrenal hyperplasia (CAH) such as 11 -hydroxylase deficiency (11OHD), some of 17-hydroxylase deficiency (17OHD), 3β-hydroxysteroid dehydrogenase deficiency (3 β HSD) and occasionally cytochrome P450 oxidoreductase defects (PORD) [6, 8, 9] . In addition, when patients show hyponatremia with no signs of hyperandrogenism, defects in 3β-hydroxysteroid dehydrogenase/isomerase (caused by HSD3B2 mutations), cholesterol side-chain cleavage enzyme (P450scc, caused by CYP11A1 mutations) and the steroidogenic acute regulatory protein (StAR, caused by StAR mutations) should be considered [9] .
Here, we report an infant boy with growth retardation, poor weight gain, failure to thrive, hyponatremia, and low plasma aldosterone. The diagnosis of ASD was finally confirmed by molecular analysis due to his atypical clinical features. This patient was found to have compound heterozygous mutations; one mutation was a reported three single nucleotide deletion, and the other was a novel nonsense mutation.
Subject and methods

Clinical manifestation and initial tests
A male infant was born apparently normal at full-term. The birth weight of this boy was 2.8 kg, and the length was 49 cm. His parents are Chinese and denied consanguinity.
He was breastfed after birth. From 2 months of age, he was referred to various local hospitals due to recurrent vomiting, poor feeding and failure to thrive. Upon medical examination at 3 months old, his body weight was 4.25 kg (-3.14 SDS) and length was 58 cm (-1.75 SDS). The patient was initially diagnosed with an allergy to formula and was treated with different formulas, but he still had repeated vomiting and poor weight gain. At 11 months of age, he was referred to our hospital for further examination. On admission, the boy was mildly dehydrated with a weight of 6 kg (-3.45 SDS) and a length of 67 cm (-3.10 SDS). He had normal external genitalia, and no hyperpigmentation was found. Then, the endocrine laboratory test for this patient was performed.
Serum DOC, corticosterone, 18OH-corticosterone and aldosterone were measured with an isotope dilution-LC-MS/MS method. Before analysis, serum samples, calibrators, and controls were thawed, mixed thoroughly, and equilibrated to room temperature. 200 μL of each sample was precisely withdrawn using a micropipette and transferred to a 5-mL glass tube. The LC-MS/MS analysis was performed using a Jasper HPLC system coupled with a triple quadruple mass spectrometer 4500MD system (Sciex Applied Biosystems, Foster City, CA, USA). Chromatographic separation was performed on an Ascentis Express F5 column (2.1 mm × 100 mm;
μm). MS/MS detection was carried out in the positive electrospray ionization mode
with multiple reaction monitoring (MRM). 
Genetic analysis
Substrate treatment and high-performance liquid chromatography (HPLC) analysis
Twenty-four hours after transfection, the cells were incubated with 1 μM DOC for 24 h. Cell culture medium was collected extracted with 1 mL of dichloromethane and concentrated under nitrogen gas. HPLC analysis was performed using an Agilent 1260 HPLC system. Samples were reconstituted in 20 μL methanol, and 7 μL were injected into the HPLC. Steroids were separated using a 50×2.1 mm, 2.6 μm, C8 Kinetex column (Phenomenex, Torrance, CA) maintained at 30°C, and samples were eluted using methanol/water gradients following methods described previously [10] . DOC, corticosterone, 18-hydroxycorticosterone and aldosterone peaks were identified by retention times of external standards chromatographed. DOC conversion was calculated using the total production of corticosterone, 18-hydroxycorticosterone and aldosterone divided by the sum of substrates and products.
Literature review
The literature regarding ASD was reviewed by searching PubMed and MEDLINE with the following key words: ASD, hypoaldosteronism, CMO deficiency and CYP11B2 mutation. The selected literature was limited to case reports written in English. References of included articles were also searched.
Statistics Analysis
All statistics analysis was performed using SPSS software version 21.0. Pearson's χ2 test / Fisher's exact test was used to show the differences of patients with and without certain phenotypes. Non-parametric test was used if data were still not normally distributed.
Results
Clinical and biochemical data
Initial laboratory examinations of the patient (Table 1) On the first visit in our hospital at the age of 11 months old, the infant was in the lifethreatening condition because of severe hyponatremia and dehydration. Intravenous fluid and sodium supplementation were given immediately in pediatric intensive care units. Steroid hormones and PRA were collected after 1 week of such treatment. The first test of PRA 0.01 ng/ml/h (Table 1 ) maybe impacted by volume and sodium supplementation. In the subsequent follow up after treatment of fludrocortisone, the second PRA was 0.6 ng/ml/h at the age of 20 months old (potassium 3.88 mmol/L and Na 138.7 mmol/L), and the third PRA was > 12 ng/ml/h at the age of 28 months old (potassium 5.09 mmol/L and Na 138.7 mmol/L).
We measured the adrenal steroids of the stored sample before fludrocortisone treatment for this boy. The result showed DOC and corticosterone were obviously increased, while the 18OH-corticosterone was in normal range ( Table 1) . As a result, the boy could be identified as ASD 1.
Genetic analysis
The patient was found to have compound heterozygous mutations with a known three single nucleotide deletion of c.1391_1393delTGC (p.Leu464del, rs776404064) and a novel nonsense mutation c.1294delA (p.Arg432Glyfs*37) in the CYP11B2 gene.
Further confirmation of these mutations was performed by amplifying exon 8 of the CYP11B2 gene by PCR, followed by direct DNA sequencing (Figure 2 ). Sanger sequencing of CYP11B2 in the parents revealed that the father was heterozygous for c.1391_1393delTGC (p.Leu464del), and the mother was heterozygous for c.1294delA
(p.Arg432Glyfs*37). 
Functional studies of novel CYP11B2 mutations
Literature review of clinical features and mutations of CYP11B2 gene
Since the ASD was a rare disease, we try to find some different clinical features in 2 subtypes in previous reported cases of ASD. Their clinical features and mutations of CYP11B2 were shown in Table 3 (Table 3 ).
Discussion
ASD is an extremely rare autosomal recessive disease in infants with typical manifestations of frequent vomiting, salt loss, dehydration and failure to thrive.
Biochemical examinations often reveal hyponatremia, hyperkalemia, elevated PRA and low levels of aldosterone. We described a Chinese boy who presented with vomiting, poor weight gain, growth retardation, and hyponatremia; however, our patient did not have an elevated PRA or markedly elevated serum potassium typical of ASD in the beginning. Similar features have been reported in other cases of ASD, [11, 12] which illustrates the variability of serum potassium in ASD. One mechanism to conserve potassium involves renal outer medullary potassium and epithelial sodium channels, which can be activated independent of aldosterone [13] .
For rare hyponatremia, steroids measurement, such as DOC, corticosterone and 18OH-corticosterone is of great significance in the diagnosis. In reported literature, approximately 50% patients underwent test (Table 3 ). It is found that DOC showed no remarkable distinction between ASD subtypes, but serum 18-hydroxycorticosterone values in patients with ASD type 2 are much higher than those in ASD type 1 patients (median, 11.4-fold versus 1.2-fold above the upper limit of normal range). In our patient, the boy showed remarkably increasing DOC and corticosterone values, while the 18OH-corticosterone was in normal range (Table 1) . In vitro tests also demonstrated undetectable intermediates or final product (Figure 3) , which is consistent with ASD 1.
Taken together, this patient could be identified as ASD 1.
To our knowledge, approximately 40 mutations in the CYP11B2 gene have been reported in cases of ASD, and missense and nonsense mutations are most common among them (Figure 4) . A majority of mutations have been found to completely destroy enzymatic activity, while in some mutations, double homozygosity is required for clinical phenotype (for instance, V386A and R181W, which are common mutations in Iranian Jewish patients with ASD). In vitro experiments indicated that p.V386A or p.R181W alone was insufficient for the disease phenotype, and only double homozygosity could cause aldosterone deficiency, with 0.2% WT activity [14] [15] [16] . ASD is a rare disease, and as far as we know, only two cases have been reported in China. One patient was compound heterozygous for c.977C>A and c.523_525delAAG, and the other patient was a compound heterozygote for mutations c.1009C>T and c.240-1G>A [17, 18] . In this study, our patient was identified as compound heterozygous for two frame shift mutations in exon 8. One mutation was the novel c.1294delA
(p.Arg432Glyfs*37) and inherited maternally, and the other mutation was c.1391_1393delTGC (p.Leu464del) and inherited paternally. The latter mutation is known as rs776404064 and has a minor allele frequency (MAF) of 0.00003 in Exome Aggregation Consortium (ExAC), while c.1294delA (p.Arg432Glyfs*37) is a novel mutation leading to a premature stop codon and thus yields a truncated protein.
Aldosterone synthesis of the encoded enzymes is impaired, as shown in Figure 3 . The truncated enzyme lacks the heme-binding motif containing Cys449, which precludes enzymatic activity [19, 20] .
A prompt diagnosis of ASD is necessary for successful treatment of the disorder. In our case, sodium chloride supplementation alone was able to maintain a serum sodium above 130 mmol/l; however, after treatment with fludrocortisone, the plasma sodium level normalized (137 mmol/L). In addition, the patient showed significant growth catch-up; after the treatment, the height and weight of the patient were -1.27 SDS and -1.08 SDS at the age of 24 months, compared with -3.45 SDS and -3.10 SDS before the treatment (Table 2 ). Other reported patients have also shown normal growth and development after treatment with fludrocortisone [21] [22] [23] [24] [25] . Consistent with previous studies, this patient illustrates a relationship between hyponatremia and failure to thrive. Salt wasting could be a factor leading to impaired growth [26, 27] , possibly due to insulin-like growth factor-1 (IGF-1) suppression or reduced extracellular fluid volume [28, 29] , but the exact mechanism of this association is not clear.
In contrast to the common dose of 100 μg/d in other cases, our patient underwent fludrocortisone therapy initiated at 75 μg/d, and gradually reduced to 50 μg/d.
Fludrocortisone treatment is essential for patients with ASD, but symptoms of salt wasting improve with age; eventually, the therapy can be discontinued for most children when they grow older. There are two main reasons why the mineralocorticoid requirements of children with ASD decrease with age. Firstly, mineralocorticoid receptors are poorly expressed in the renal epithelium of newborns and this increases with age, thus increasing sensitivity to mineralocorticoids [30, 31] . Secondly, newborn diets (especially mothers' milk) had low content of sodium, and dietary sodium increased with age with transition to 'table foods'. Other reasons mentioned before including increased sodium reabsorption due to mature renal tubules and alternative pathway of mineralocorticoid biosynthesis [32, 33] . Recent studies recommend an initial dose of 100-200 μg/day, and the dose should be adjusted regularly according to clinical and laboratory data, such as blood pressure, serum sodium and potassium, and plasma renin activity [30, 34] .
Hypoaldosteronism and hyponatremia can be seen in many diseases. ASD is readily suspected based on typical clinical manifestations, but accurate diagnosis can be difficult when patients present atypical features, such as for our child. Given our limited ability to measure diagnostic steroids, we employed NGS technologies with a custom panel to arrive at a molecular diagnosis, while fludrocortisone therapy was instituted.
Conclusion
Here, we described a rare case of ASD in a Chinese male infant with molecular analysis, and functional studies in vitro further confirmed the impaired aldosterone synthesis by the encoded enzymes. ASD should be considered in infants presenting with poor feeding, salt wasting and failure to thrive but not virilism. Our study indicates that typical features of ASD are not always observed, and fludrocortisone treatment is required in infants to improve clinical features and to enable catchup growth. The in vitro tests of enzyme function were consistent with ASD type 1.
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